Penka S. Petrova

1.2k citations

22 papers · 546 indexed · h-index 9

Developmental Neuroscience top 10%
Immunology
- Phagocytosis and Immune Regulation 16
- Immune cells in cancer 7
- Immunotherapy and Immune Responses 5
- Complement system in diseases 4
- Immune Cell Function and Interaction 3
Cellular and Molecular Neuroscience top 10%
Cell Biology top 10%
Aging
Surgery
- Pancreatic function and diabetes 4
Oncology
- CAR-T cell therapy research 3
Physiology
- Erythrocyte Function and Pathophysiology 3

Co-authors: Mordechai Anafi Jonathan Pevsner Yves Durocher John Kelly Jeremy C. Smith John W. Commissiong Amy Peaire Viji Shridhar
Cited by: Developmental Neuroscience Immunology Cellular and Molecular Neuroscience
Journals: Journal of Clinical Oncology (2 papers)Blood (8 papers)PLoS ONE (1 paper)
Partner nations: United States Canada United Kingdom

In The Last Decade

Penka S. Petrova

22 papers receiving 535 citations

Peers

Countries citing papers authored by Penka S. Petrova

Since Specialization

Citations

This map shows the geographic impact of Penka S. Petrova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Penka S. Petrova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Penka S. Petrova more than expected).

Fields of papers citing papers by Penka S. Petrova

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Penka S. Petrova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Penka S. Petrova. The network helps show where Penka S. Petrova may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Penka S. Petrova, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Penka S. Petrova Line = papers co-authored together Penka S. Petrova links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study The Lancet Haematology ·Christiane Querfeld,John A. Thompson,Matthew H. Taylor,Jennifer DeSimone,Jasmine Zain,Andrei R. Shustov,Carolyn Johns,Sue McCann,Gloria H. Y. Lin,Penka S. Petrova,Robert A. Uger,Naomi Molloy,Yaping Shou,Oleg E. Akilov	2021	56
2	CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study Blood ·Krish Patel,Jeffrey A. Zonder,Dahlia Sano,Michael B. Maris,Alexander M. Lesokhin,Gottfried von Keudell,Catherine Lai,Rod Ramchandren,Tina Catalano,Gloria H. Y. Lin,Bob Uger,Penka S. Petrova,Naomi Molloy,Ingmar Bruns,Swaminathan P. Iyer	2021	20
3	Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study Blood ·Krish Patel,Radhakrishnan Ramchandren,Michael B. Maris,Alexander M. Lesokhin,Gottfried R. von Keudell,Bruce D. Cheson,Jeff Zonder,Erlene Seymour,Tina Catalano,Gloria H. Y. Lin,Bob Uger,Penka S. Petrova,Kathleen Roberge,Yaping Shou,Swaminathan P. Iyer	2020	14
4	Abstract 2720: The CD47-blocking innate immune checkpoint inhibitor, TTI-621, triggers CD47-mediated tumor cell apoptosis Cancer Research ·Julia Izrailit,Natasja Nielsen Viller,Xinli Pang,Penka S. Petrova,Robert A. Uger,Jeff Winston,Emma Linderoth	2018	1
5	Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Interim Results of a Multicenter Phase I Trial Blood ·Christiane Querfeld,John A. Thompson,Matthew H. Taylor,Raju Pillai,Lisa D. Johnson,Tina Catalano,Penka S. Petrova,Theresa Thompson,Robert A. Uger,Yaping Shou,Oleg E. Akilov	2018	8
6	Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sézary syndrome: Interim results of a multicenter Phase 1 trial European Journal of Cancer ·Christiane Querfeld,John A. Thompson,Matthew H. Taylor,Raju Pillai,Lisa D. Johnson,Tina Catalano,Penka S. Petrova,Bob Uger,Meghan Irwin,Theresa Thompson,Eric L. Sievers,Oleg E. Akilov	2018	7
7	Investigating the Efficacy of Anti-CD200 Immunotherapy in MRD Low and Risk B Cell Precursor ALL Blood ·Paraskevi Diamanti,Saifurrizal Saifurrizal,Charlotte V. Cox,Penka S. Petrova,Robert A. Uger,Allison Blair	2017	1
8	A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 Do Not Eat Signal Blood ·Christiane Querfeld,John A. Thompson,Matthew H. Taylor,Raju Pillai,Lisa D. Johnson,Tina Catalano,Penka S. Petrova,Robert A. Uger,Meghan Irwin,Eric L. Sievers,Oleg E. Akilov	2017	15
9	TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets PLoS ONE ·Gloria H. Y. Lin,Vien Chai,Vivian Lee,Karen Dodge,Tran Truong,Mark Wong,Lisa D. Johnson,Emma Linderoth,Xinli Pang,Jeff Winston,Penka S. Petrova,Robert A. Uger,Natasja Nielsen Viller	2017	51
10	Abstract 2646: Intratumoral delivery of TTI-621 (SIRPαFc), a CD47-blocking immunotherapeutic, inhibits tumor growth and prolongs animal survival in a subcutaneous B cell lymphoma model Cancer Research ·Gloria H. Y. Lin,Marilyse Charbonneau,Vien Chai,Alison O’Connor,Bolette Bossen,Hui Chen,Mark Wong,Natasja Nielsen Viller,Emma Linderoth,Lisa D. Johnson,Xinli Pang,Jeffery Winston,Penka S. Petrova,Robert A. Uger	2017	1
11	A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides. Journal of Clinical Oncology ·John A. Thompson,Oleg E. Akilov,Christiane Querfeld,Matthew H. Taylor,Lisa D. Johnson,Tina Catalano,Penka S. Petrova,Robert A. Uger,Meghan Irwin,Eric L. Sievers	2017	4
12	Effects of TTI-621 (SIRPαFc) on CD47 and serum cytokines associated with phagocytosis in subjects with relapsed, refractory hematologic malignancies: Pharmacodynamic findings from a first-in-human clinical trial. Journal of Clinical Oncology ·Lisa D. Johnson,Raju Pillai,Rebecca L. King,Stephen M. Ansell,Robert W. Chen,Ian W. Flinn,Michael B. Maris,Meghan Irwin,Eric L. Sievers,Penka S. Petrova,Robert A. Uger	2017	3
13	Abstract 2345: SIRPαFc, a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by both classically (M1) and alternatively (M2) activated macrophages Cancer Research ·Gloria H. Y. Lin,Vien Chai,Vivian Lee,Karen Dodge,Tran Truong,Mark Wong,Lisa D. Johnson,Xinli Pang,Penka S. Petrova,Robert A. Uger,Natasja Nielsen Viller	2016	1
14	Abstract B028: Blockade of the CD47 “Do not eat” signal by TTI-621 (SIRPαFc) leads to enhanced antitumor CD8+ T cell responses in vitro Cancer Immunology Research ·Natasja Nielsen Viller,Tran Truong,Emma Linderoth,Lisa D. Johnson,Stéphane Viau,Gloria H. Y. Lin,Mark Wong,Xinli Pang,Penka S. Petrova,Robert A. Uger	2016	1
15	Investigating the Effects of Anti-CD200 Therapy for Childhood ALL Blood ·Paraskevi Diamanti,Charlotte V. Cox,Benjamin C. Ede,Penka S. Petrova,Robert A. Uger,Allison Blair	2016	2
16	Abstract 4271: Lack of CD47 membrane mobility contributes to the poor erythrocyte binding of SIRPαFc, a novel CD47-blocking cancer immunotherapeutic Cancer Research ·Penka S. Petrova,Karen Dodge,Tanya Prasolava,Vien Chai,Xinli Pang,Robert A. Uger	2015	1
17	Abstract 5011: Cancer immunotherapy targeting CD47: Wild type SIRPαFc is the ideal CD47-blocking agent to minimize unwanted erythrocyte binding Cancer Research ·Robert A. Uger,Karen Dodge,Xinli Pang,Penka S. Petrova	2014	2
18	Blockade Of CD47 Using SIRPαFc: Role Of The Fc Region In Anti-Leukemic Activity and Tolerability Blood ·Robert A. Uger,Xinli Pang,Mark Wong,Violetta House,Karen Dodge,Stéphane Viau,Noel T. Vigo,Debbie Tam,Tran Truong,Liqing Jin,Andrei V. Malko,Jenny Ho,Tatiana K. Prasolava,Jayne S. Danska,Jean Wang,Penka S. Petrova	2013	3
19	Discovering novel phenotype-selective neurotrophic factors to treat neurodegenerative diseases Progress in brain research ·Penka S. Petrova,Andrei Raibekas,Jonathan Pevsner,Noel Vigo,Mordechai Anafi,Mary Kate Moore,Amy Peaire,Viji Shridhar,Jeremy C. Smith,John Kelly,Yves Durocher,John W. Commissiong	2004	30
20	MANF: A New Mesencephalic, Astrocyte-Derived Neurotrophic Factor with Selectivity for Dopaminergic Neurons Journal of Molecular Neuroscience ·Penka S. Petrova,Andrei Raibekas,Jonathan Pevsner,Noel Vigo,Mordechai Anafi,Mary Kate Moore,Amy Peaire,Viji Shridhar,Jeremy C. Smith,John Kelly,Yves Durocher,John W. Commissiong	2003	290

About Penka S. Petrova

Penka S. Petrova is a scholar working on Immunology, Developmental Neuroscience and Neurology, having authored 22 papers that have together received 546 indexed citations. Recurring topics across this work include Phagocytosis and Immune Regulation (16 papers), Immune cells in cancer (7 papers), Immunotherapy and Immune Responses (5 papers), Complement system in diseases (4 papers), Pancreatic function and diabetes (4 papers), CAR-T cell therapy research (3 papers), Erythrocyte Function and Pathophysiology (3 papers) and Immune Cell Function and Interaction (3 papers). The work is most often cited by research in Developmental Neuroscience (46 citations), Immunology (213 citations) and Cellular and Molecular Neuroscience (163 citations). Penka S. Petrova has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Mordechai Anafi, Jonathan Pevsner, Yves Durocher, John Kelly, Jeremy C. Smith, John W. Commissiong, Amy Peaire, Viji Shridhar, Robert A. Uger and Gloria H. Y. Lin. Their work appears in journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact